Topical therapy for dermatophytoses: Should corticosteroids be included?

American Journal of Clinical Dermatology

Volumn 5, Issue 6, 2004, Pages 375-384

  Erbagci, Zulal ^a,b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Gazimuhtarpasa Bulvari   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BETAMETHASONE DIPROPIONATE; BIFONAZOLE; BUTENAFINE; CICLOPIROX; CLOBETASONE BUTYRATE; CLOTRIMAZOLE; CORTICOSTEROID; ECONAZOLE; FENTICONAZOLE; FLUCONAZOLE; FUSIDATE SODIUM; GRISEOFULVIN; HALOPROGIN; HYDROCORTISONE; ITRACONAZOLE; KETOCONAZOLE; METHYLENE BLUE; NAFTIFINE; OXICONAZOLE; SELENIUM SULFIDE; SERTACONAZOLE; SULCONAZOLE; TERBINAFINE; TIOCONAZOLE; TOLNAFTATE; WHITFIELD OINTMENT;

ADRENAL SUPPRESSION; CANDIDIASIS; CUSHING SYNDROME; DERMATOMYCOSIS; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG MECHANISM; EPIDERMOPHYTON; GROWTH RETARDATION; HIRSUTISM; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL HYPERTENSION; LONG TERM CARE; MICROSPORUM; ONYCHOMYCOSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUVA; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SKIN MANIFESTATION; TINEA; TINEA BARBAE; TINEA CAPITIS; TINEA CORPORIS; TINEA CRURIS; TINEA PEDIS; TOPICAL TREATMENT; TRICHOPHYTON;

ADMINISTRATION, CUTANEOUS; ADRENAL CORTEX HORMONES; ANTIFUNGAL AGENTS; CANDIDIASIS, CUTANEOUS; DERMATOMYCOSES; DRUG THERAPY, COMBINATION; HUMANS; TINEA; TREATMENT OUTCOME;

EID: 12944297626     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200405060-00002     Document Type: Review

References (76)

1. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8 (2): 240-59
2. Weinstein A, Herman B. Topical treatment of common superficial tinea infections. Am Fam Physician 2002 May 15; 65: 2095-102
3. Rippon JW. Medical mycology: the pathogenic fungi and pathogenic actinomycetes. 3rd ed. Philadelphia (PA): WB Saunders Company, 1988: 169-275
4. Wagner DK, Sohnle PG. Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev 1995; 8: 317-35
5. Elewski B, Sullivan J. Dermatophytes as opportunistic pathogens. J Am Acad Dermatol 1994; 30: 1021-2
6. Smith KJ, Welsh M, Skelton H. Trichophyton rubrum showing deep dermal invasion directly from the epidermis in immunosuppressed patients. Br J Dermatol 2001; 145: 344-8
7. Chastain MA, Reed RJ, Pankey GA. Deep dermatophytosis: report of 2 cases and review of the literature. Cutis 2001; 67: 457-62
8. Radentz WH, Yanase DJ. Papular lesions in an immunocompromised patient. Arch Dermatol 1993; 129: 1189-90
9. Erbagci Z. Deep dermatophytoses in association with atopy and diabetes mellitus: Majocchi's granuloma tricophyticum or dermatophytic pseudomycetoma? Mycopathologia 2002; 154: 163-9
10. Abraham AG, Kulp-Shorten CL, Callen JP. Remember to consider dermatophyte infection when dealing with recalcitrant dermatoses. South Med J 1998; 91: 349-53
11. Demidovich CW, Kornfeld BW, Gentry RH, et al. Deep dermatophyte infection with draining nodules in an immunocompromised patient. Cutis 1995; 55: 237-40
12. Okuwa T, Horio T. The inhibitory effect of PUVA on the immunity of experimental dermatophytosis in guinea pigs. Arch Dermatol Res 1986; 278: 320-3
13. Jones HE. The atopic-dermatophytosis syndrome. Acta Derm Venereol Suppl 1980; 92: 81-5
14. Tagami H, Kudoh K, Takematsu H. Inflammation and immunity in dermatophytosis. Dermatologica 1989; 179 Suppl. 1: 1-8
15. Stahl D, Svejgaard E. Lymphocyte transformation in vitro in acute dermatophytosis: a follow-up study. Acta Derm Venereol 1982; 69: 289-93
16. Jones HE. Immune response and host resistance of humans to dermatophyte infections. J Am Acad Dermatol 1993; 28: S12-18
17. Braathen LR, Kaman T. Human epidermal Langerhans cells induce cellular immune response to trichophytin response in dermatophytosis. Br J Dermatol 1983; 109: 295-300
18. Swejgaard E. Humoral antibody responses in the immunopathogenesis of dermatophytosis. Acta Derm Venereol (Stockh.) 1986; 121: 85-91
19. Calderon RA, Hay RJ. Fungicidal activity of human neutrophils and monocytes on dermatophyte fungi, Trichophyton quinckeanum and Trichophyton rubrum. Immunology 1987; 61: 289-95
20. Novick NL, Tapia L, Bottone EJ. Invasive Trichophyton rubrum infection in an immunocompromised host: case report and review of the literature. Am J Med 1987; 82: 321-5
21. Diehl KB. Topical antifungal agents: an update. Am Fam Physician 1996; 54: 1687-92
22. Ganzinger U, Stutz A, Petranyi G, et al. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents. Acta Derm Venereol Suppl (Stockh.) 1986; 121: 155-60
23. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126 Suppl. 39: 2-7
24. Evans EG, James IG, Seaman RA, et al. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br J Dermatol 1993; 129: 437-42
25. Nada M, Hanafi S, al-Omari H, et al. Naftifine versus miconazole/hydrocortisone in inflammatory dermatophyte infections. Int J Dermatol 1994; 33: 570-2
26. Smith EB, Breneman DL, Griffith RF, et al. Double-blind comparison of naftifine cream and clotrimazole/betamethasone diproprionate cream in the treatment of tinea pedis. J Am Acad Dermatol 1992; 26: 125-7
27. Tronnier H. Inflammatory dermatomycoses-comparative study of naftifine and a combination of a corticosteroid and an imidazole derivative. Mykosen 1987; 30: 78-87
28. Evans EG, Seaman RA, James IG. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections. Br J Dermatol 1994; 130: 83-7
29. Smith ES, Fleischer Jr AB, Feldman SR. Nondermatologists are more likely than dermatologists to prescribe antifungal/corticosteroid products: an analysis of office visits for cutaneous fungal infections, 1990-1994. J Am Acad Dermatol 1998; 39: 43-7
30. Greenberg HL, Shwayder TA, Bieszk N, et al. Clotrimazole/betamethasone diproprionate: a review of costs and complications in the treatment of common cutaneous fungal infections. Pediatr Dermatol 2002; 19: 78-81
31. Shaffer MP, Feldman SR, Fleischer Jr AB. Use of clotrimazole/ betamethasone diproprionate by family physicians. Fam Med 2000; 32: 561-5
32. Fleischer Jr AB, Feldman SR. Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. Clin Ther 1999; 21: 1725-31
33. Railan D, Wilson JK, Feldman SR, et al. Pediatricians who prescribe clotrimazole-betamethasone diproprionate (Lotrisone) often utilize it in inappropriate settings regardless of their knowledge of the drug's potency. Dermatol Online J 2002; 8: 3
34. Rang HP, Dale MM. Pharmacology. 2nd ed. Hong Kong: Churchill Livingstone, 1991: 510-9
35. Frances C. Practical application of local corticotherapy: topical corticosteroids [in French]. Rev Prat 1990 Feb 21; 40 (6): 527-30
36. Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh.) 1989; 151: 7-10
37. Samsun C, Peets E, Winter-Sperry R, et al. Clotrimazole/betamethasone diproprionate-Lotrisone: an antifungal/steroid combination for treatment of cutaneous dermatophyte infection. In: Maibach HI, Surber C, editors. Topical corticosteroids. Basel: Karger, 1992: 318-34
38. La Grenade L, Vega A, Luke MC. Adverse effects of Lotrisone cream used in infants. Pediatrics 2000; 106: 519-20
39. Gorani A, Schiera A, Oriani A. Case report: rosacea-like tinea incognitio. Mycoses 2002; 45: 135-7
40. Almeida L, Grossman M. Widespread dermatophyte infection that mimic collagen vascular disease. J Am Acad Dermatol 1990; 23: 855-7
41. Reynolds RD, Boiko S, Lucky AW. Exacerbation of tinea corporis during treatment with 1% clotrimazole/0.05% betamethasone diproprionate (Lotrisone). Am J Dis Child 1991; 145: 1224-5
42. Rosen T, Elewski BE. Failure of clotrimazole-betamethasone diproprionate cream in treatment of Microsporum canis infections. J Am Acad Dermatol 1995; 32: 1050-1
43. Barkey WF. Striae and persistent tinea corporis related to prolonged use of betamethasone dipropionate 0.05% cream/clotrimazole 1% cream (Lotrisone cream). J Am Acad Dermatol 1987; 17: 518-9
44. Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics 2003; 111: 201-3
45. Ive FA, Marks R. Tinea incognitio. BMJ 1968; 3: 149-52
46. Jacobs JA, Kolbach DN, Vermeulen AH, et al. Tinea incognito due to Trichophytom rubrum after local steroid therapy. Clin Infect Dis 2001; 33: E142-144
47. Solomon BA, Glass AT, Rabbin PE. Tinea incognito and 'over-the-counter' potent topical steroids. Cutis 1996; 58: 295-6
48. Toler T. Tinea incognito and over-the-counter potent topical steroids [letter]. Cutis 1997; 59 (4): 295-6
49. Feder Jr HM. Tinea incognito misdiagnosed as erythema migrans. N Engl J Med 2000; 343 (1): 69
50. Elgart ML. Tinea incognito: an update on Majocchi granuloma. Dermatol Clin 1996; 14 (1): 51-5
51. Chen AW, Kuo KWL, Chen JS, et al. Dermatophyte pseudomycetoma: a case report. Br J Dermatol 1993; 129: 729-32
52. Degreef H, Dooms-Goossens A. The new corticosteroids: are they effective and safe? Dermatol Clin 1993; 11: 155-60
53. Adams BB, Sheth PB. Perianal ulcerations from topical steroid use. Cutis 2002; 69: 67-8
54. Korting HC, Kerscher MJ, Schafer-Korting M. Topical glucocorticoids with improved benefit/risk ratio: do they exist? J Am Acad Dermatol 1992; 27: 87-92
55. Erbagci Z, Balci I, Erkilic S, et al. Cutaneous hyalohyphomycosis and onychomycosis caused by Onychocola canadensis: report of the first case from Turkey. J Dermatol 2002; 29: 522-8
56. Raab W. Behandlung von Mykosen mit Corticoid-haltigen Praparaten. Hautarzt 1975; 26: 349-51
57. Raab W. Antimycotic substances and corticosteroids [in German]. Arch Klin Exp Dermatol 1968; 231: 250-63
58. Raab W, Hogl F. The influence of glucocorticoids on the inhibition of enzymatic activities exerted by antifungal imidazole derivatives [in German]. Mykosen 1982; 25: 303-14
59. Hogl F, Raab W. The influence of glucocorticoids on the membrane disrupting activity of antifungal imidazole derivatives [author's translation in German]. Mykosen 1982; 25 (6): 315-20
60. Hogl F, Raab W. The influence of steroids on the antifungal and antibacterial activities of imidazole derivatives [author's translation in German]. Mykosen 1980; 23 (8): 426-39
61. Raab W, Gmeiner B. Interactions between econazole, a broad-spectrum antimicrobic substance, and topically active glucocorticoids. Dermatologica 1976; 153: 14-22
62. Raab W, Killer S. Haloprogin: its effects in the presence of glucocorticoids and neomycin [in German]. Z Hautkr 1975; 50: 499-505
63. Katz HI, Bard J, Cole GW, et al. SCH 370 (clotrimazole-betamethasone dipropionate) cream in patients with tinea cruris or tinea corporis. Cutis 1984; 34: 183-8
64. Shankland GS, Richardson MD. Comparative in-vivo activity of clotrimazole and a clotrimazole/hydrocortisone combination in the treatment of experimental dermatophytosis in guinea pigs. J Antimicrob Chemother 1990; 25: 825-30
65. Shankland GS, Richardson MD. Treatment of experimental dermatophytosis in guinea pigs: a comparative study of bifonazole and a bifonazole-hydrocortisone combination. Mycoses 1989; 32: 139-44
66. Wachs GN, Maibach HI. Co-operative double-blind trial of an antibiotic/corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323-8
67. Pazzaglia A. Therapeutic effects and tolerance of an extempore combination of an antibacterial, an anti-inflammatory, and an antimycotic cream in skin diseases of various origins. Pharmatherapeutica 1985; 4: 122-5
68. Nolting S, Rogalla K. Double-blind comparison of miconazole/ corticosteroid combination versus miconazole in inflammatory dermatomycoses. Int J Dermatol 1995; 34: 125-8
69. Carbone F. Combination of an antiinflammatory steroid, an antibacterial agent an antifungal agent. Clin Trials J 1985; 22: 158-64
70. Bowring ARW, Mackay D, Taylor FR. The treatment of napkin dermatitis: a double-blind comparison of two steroid-antibiotic combinations. Pharmatherapeutica 1984; 3: 613-7
71. Szarmach H, Weuta H, Stepka L. Indikationsabgrenzung zwischen Clotrimazol/ Hydrocortison und seining beiden Komponenten. Ein doppelblinde Studie. Arzneimittelforschung 1984; 34: 927-30
72. Wortzel MH. A double-blind study comparing the superiority of a combination antifungal (clotrimazole)/steroidal (betamethasone dipropianate) product. Cutis 1982; 30: 258-61
73. Pariser RJ, Pariser DM. Clinical and mycological effect of clotrimazole/ betamethasone dipropionate cream versus ketoconazole cream in patients with tinea cruris. J Dermatol Treat 1995; 6: 173-7
74. Elewski BE, Jones T, Zaias N. Comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory tinea pedis. Cutis 1996; 58: 305-7
75. Raab W. Effects of local corticosteroids in skin infections. Dermatologica 1976; 152 Suppl. 1: 67-79
76. Fleisher AB, Feldman SR. Prescribing and cost analysis of treatments of cutaneous fungal infections: reply [letter]. J Am Acad Dermatol 1999; 40: 1014-5